Page last updated: 2024-12-06
dehydrocorydalin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
dehydrocorydalin: alkaloid from Corydalis bulbuso D.C. used in therapy of peptic ulcer; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Corydalis | genus | A plant genus of the family FUMARIACEAE (classified by some in PAPAVERACEAE) that contains isoquinoline alkaloids.[MeSH] | Papaveraceae | The poppy plant family of the order Papaverales, subclass Magnoliidae, class Magnoliopsida. These have bisexual, regular, cup-shaped flowers with one superior pistil and many stamens; 2 or 3 conspicuous, separate sepals and a number of separate petals. The fruit is a capsule. Leaves are usually deeply cut or divided into leaflets.[MeSH] |
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 34781 |
| CHEMBL ID | 1917176 |
| CHEBI ID | 81342 |
| SCHEMBL ID | 14513602 |
| MeSH ID | M0050292 |
Synonyms (29)
| Synonym |
|---|
| 7,8,13,13a-tetradehydro-2,3,9,10-tetramethoxy-13-methylberbinium |
| brn 1556798 |
| dehydrocorydalin |
| dibenzo(a,g)quinolizinium, 5,6-dihydro-2,3,9,10-tetramethoxy-13-methyl- |
| berbinium, 7,8,13,13a-tetradehydro-2,3,9,10-tetramethoxy-13-methyl- |
| dehydrocorydaline |
| 2,3,9,10-tetramethoxy-13-methyl-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium |
| 30045-16-0 |
| C17790 |
| S9431 |
| 5-21-06-00206 (beilstein handbook reference) |
| CHEMBL1917176 |
| chebi:81342 , |
| FT-0624497 |
| dibenzo[a,g]quinolizinium,5,6-dihydro-2,3,9,10-tetramethoxy-13-methyl- |
| SCHEMBL14513602 |
| Q-100383 |
| HY-N0674 |
| AKOS030526131 |
| Q27155279 |
| A14669 |
| CCG-268242 |
| 13-methylpalmatine |
| DTXSID30904183 |
| AC-34813 |
| EX-A6791 |
| bdbm50594956 |
| 2,3,9,10-tetramethoxy-13-methyl-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium |
| A924184 |
Research Excerpts
Overview
Dhydrocorydaline (DHC) is an alkaloid isolated from Corydali syanhusuo. It exhibits antitumor properties.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Dehydrocorydaline (DHC) is an alkaloid isolated from Corydali syanhusuo that exhibits antitumor properties. " | ( Dehydrocorydaline inhibits the tumorigenesis of breast cancer MDA‑MB‑231 cells. Chen, F; Huang, H; Huang, Y; Wang, S; Zheng, G, 2020) | 3.44 |
| "Dehydrocorydaline (DHC) is an alkaloidal component isolated from Rhizoma corydalis. " | ( Antinociceptive effects of dehydrocorydaline in mouse models of inflammatory pain involve the opioid receptor and inflammatory cytokines. Chu, SS; Gu, XP; Li, L; Ma, ZL; Sun, Q; Yin, ZY, 2016) | 2.17 |
| "Dehydrocorydaline is an alkaloid isolated from traditional Chinese herb Corydalis yanhusuo W.T. " | ( Dehydrocorydaline inhibits breast cancer cells proliferation by inducing apoptosis in MCF-7 cells. Bao, J; Chen, L; Chen, X; Dang, Y; Fu, S; Huang, M; Wang, Y; Xu, Z, 2012) | 3.26 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " The method was applied to a pharmacokinetic study of THP and DHC after oral administration of the total alkaloid extraction of Rhizoma Corydalis (Yanhusuo)." | ( [Pharmacokinetic studies of tetrahydropalmatine and dehydrocorydaline in rat after oral administration of yanhusuo extraction by LC-MS/MS method]. Duan, CL; Lin, CR; Lin, L; Liu, JX; Zhang, Y, 2008) | 0.6 |
| " The pharmacokinetic parameters showed that DHC from EFY was absorbed more rapidly and eliminated more slowly than pure DHC." | ( LC-MS/MS determination and pharmacokinetic study of dehydrocorydaline in rat plasma after oral administration of dehydrocorydaline and Corydalis yanhusuo extract. Jin, W; Li, KT; Li, QY; Shi, JW; Shi, Y; Sun, H, 2014) | 0.65 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| alkaloid | Any of the naturally occurring, basic nitrogen compounds (mostly heterocyclic) occurring mostly in the plant kingdom, but also found in bacteria, fungi, and animals. By extension, certain neutral compounds biogenetically related to basic alkaloids are also classed as alkaloids. Amino acids, peptides, proteins, nucleotides, nucleic acids, amino sugars and antibiotics are not normally regarded as alkaloids. Compounds in which the nitrogen is exocyclic (dopamine, mescaline, serotonin, etc.) are usually classed as amines rather than alkaloids. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Lysine-specific histone demethylase 1A | Homo sapiens (human) | IC50 (µMol) | 2.4400 | 0.0031 | 2.1602 | 9.6000 | AID1872430 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (32)
Molecular Functions (22)
Ceullar Components (7)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| chromatin | Lysine-specific histone demethylase 1A | Homo sapiens (human) |
| nucleus | Lysine-specific histone demethylase 1A | Homo sapiens (human) |
| chromosome, telomeric region | Lysine-specific histone demethylase 1A | Homo sapiens (human) |
| nucleus | Lysine-specific histone demethylase 1A | Homo sapiens (human) |
| nucleoplasm | Lysine-specific histone demethylase 1A | Homo sapiens (human) |
| transcription regulator complex | Lysine-specific histone demethylase 1A | Homo sapiens (human) |
| protein-containing complex | Lysine-specific histone demethylase 1A | Homo sapiens (human) |
| DNA repair complex | Lysine-specific histone demethylase 1A | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID627754 | Binding affinity to STAT3 G-quadruplex in 3'-flanking region 5'-GGGCTGGGGATGGGGAGGGGG-3' assessed as intensity ratio of all complex ions to the sum of all G-quadruplex and complex ions at 20 uM by ESI mass spectroscopy relative to control | 2011 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19 | Formation, recognition and bioactivities of a novel G-quadruplex in the STAT3 gene. |
| AID1872430 | Inhibition of KDM1A (unknown origin) by fluorescence based assay | 2022 | European journal of medicinal chemistry, Mar-05, Volume: 231 | Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present). |
| AID1871466 | Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation at 150.8 uM preincubated for 3 mins followed by ADP addition and measured after 5 mins relative to control | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (37)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (10.81) | 18.7374 |
| 1990's | 3 (8.11) | 18.2507 |
| 2000's | 8 (21.62) | 29.6817 |
| 2010's | 17 (45.95) | 24.3611 |
| 2020's | 5 (13.51) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.28
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.28) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (2.56%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 38 (97.44%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||